Top Stories
The findings point to a potential new way to monitor the disease without repeated tissue biopsies.
The money will fund a pivotal trial of StimCardio's Rhyvive wearable following promising early results.
The company's virtual mental health business saw insurance-covered therapy revenue reach $32.1 million, helping offset a sharp decline in direct-to-consumer sales.
Etcelera was born from the bones of Cellarity, Etiome and Empress Therapeutics.
The findings could help refine patient selection and shape the design of future stroke trials.
Conference News
First plaque tool with prospective outcomes data. Faster, sustained LDL-C control: approximately 50% of patients reached goal by 90 days vs. approximately 35% with CCTA alone. GAMEFILM data highlight ...
Device demonstrated higher specificity than standard 12-lead ECG (81.8% vs. 71.4%), with comparable sensitivityHeartBeam ECGs were interpreted more consistently across cardiologists than standard 12-l...
Research Highlights:Health professionals not previously trained in ultrasound were able to perform quality heart scans in a mobile unit that traveled to rural U.S. communities with training and real-t...
ACLF – Advancing a multi-target therapeutic strategyGENFIT to host a scientific event on November 8, 2026 to outline its ACLF strategy and unveil a comprehensive clinical data package supporting the a...
Extra-wide-bore, cable-less ceiling gantry and real-time digital twin aim to keep cases moving, regardless of procedure type or patient sizeAI-powered precision imaging designed to automatically balan...
